Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer
Although the recently approved prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) [177Lu]Lu-PSMA-617 has improved outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC), not all patients respond optimally to this treatment; even measuring respons...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1583168/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849233419225006080 |
|---|---|
| author | Himisha Beltran Jeremie Calais Louise Emmett Phillip H. Kuo Christopher J. Logothetis |
| author_facet | Himisha Beltran Jeremie Calais Louise Emmett Phillip H. Kuo Christopher J. Logothetis |
| author_sort | Himisha Beltran |
| collection | DOAJ |
| description | Although the recently approved prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) [177Lu]Lu-PSMA-617 has improved outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC), not all patients respond optimally to this treatment; even measuring response accurately can be difficult. Moreover, there is currently a lack of validated prognostic and predictive biomarkers for [177Lu]Lu-PSMA-617 treatment in this patient population. There is, therefore, a growing need to identify biomarkers to help optimize patient selection for [177Lu]Lu-PSMA-617 and guide therapy decision-making. This review explores the landscape of emerging clinical, molecular, and imaging biomarkers, and their potential utility as prognostic and/or predictive biomarkers in the context of [177Lu]Lu-PSMA-617 treatment for patients with mCRPC. |
| format | Article |
| id | doaj-art-9a6b36d99ee246a4ae29133515b092e1 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-9a6b36d99ee246a4ae29133515b092e12025-08-20T05:32:43ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-08-011510.3389/fonc.2025.15831681583168Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancerHimisha Beltran0Jeremie Calais1Louise Emmett2Phillip H. Kuo3Christopher J. Logothetis4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United StatesAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA, United StatesDepartment of Theranostics and Nuclear Medicine, St Vincent’s Hospital Sydney, St Vincent’s Clinical School, University of New South Wales, Sydney, NSW, AustraliaDepartment of Radiology, City of Hope National Medical Center, Duarte, CA, United StatesDepartment of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, United StatesAlthough the recently approved prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) [177Lu]Lu-PSMA-617 has improved outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC), not all patients respond optimally to this treatment; even measuring response accurately can be difficult. Moreover, there is currently a lack of validated prognostic and predictive biomarkers for [177Lu]Lu-PSMA-617 treatment in this patient population. There is, therefore, a growing need to identify biomarkers to help optimize patient selection for [177Lu]Lu-PSMA-617 and guide therapy decision-making. This review explores the landscape of emerging clinical, molecular, and imaging biomarkers, and their potential utility as prognostic and/or predictive biomarkers in the context of [177Lu]Lu-PSMA-617 treatment for patients with mCRPC.https://www.frontiersin.org/articles/10.3389/fonc.2025.1583168/fullmetastatic castration-resistant prostate cancerprostate-specific membrane antigenradioligand therapy[177Lu]Lu-PSMA-617biomarkers |
| spellingShingle | Himisha Beltran Jeremie Calais Louise Emmett Phillip H. Kuo Christopher J. Logothetis Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer Frontiers in Oncology metastatic castration-resistant prostate cancer prostate-specific membrane antigen radioligand therapy [177Lu]Lu-PSMA-617 biomarkers |
| title | Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer |
| title_full | Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer |
| title_fullStr | Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer |
| title_full_unstemmed | Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer |
| title_short | Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer |
| title_sort | biomarkers to optimize psma targeted radioligand therapy for metastatic castration resistant prostate cancer |
| topic | metastatic castration-resistant prostate cancer prostate-specific membrane antigen radioligand therapy [177Lu]Lu-PSMA-617 biomarkers |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1583168/full |
| work_keys_str_mv | AT himishabeltran biomarkerstooptimizepsmatargetedradioligandtherapyformetastaticcastrationresistantprostatecancer AT jeremiecalais biomarkerstooptimizepsmatargetedradioligandtherapyformetastaticcastrationresistantprostatecancer AT louiseemmett biomarkerstooptimizepsmatargetedradioligandtherapyformetastaticcastrationresistantprostatecancer AT philliphkuo biomarkerstooptimizepsmatargetedradioligandtherapyformetastaticcastrationresistantprostatecancer AT christopherjlogothetis biomarkerstooptimizepsmatargetedradioligandtherapyformetastaticcastrationresistantprostatecancer |